ALLEGAN, Mich.—The generics pharmaceutical company Padagis is investing more than $36 million to expand its manufacturing operations in Minneapolis, Minnesota, enhancing its capacity to domestically produce and package naloxone nasal spray.
The expansion marks a major step in Padagis’ multi-year initiative to onshore production of life-saving medications. The company began implementing its U.S. expansion plans in 2023 and expects to begin naloxone manufacturing in Minnesota in the fourth quarter of 2025, with full operational readiness in 2026.
“This is more than an investment — it’s a commitment to saving lives,” said Pamela Hoffman, president of Padagis. “By bringing naloxone production to the U.S., we can respond faster in times of urgent need and ensure this critical medication is always within reach for the communities who need it most.”
The Minneapolis expansion will boost Padagis’ production capacity, enhance supply chain resilience, and lessen reliance on overseas shipping. The company stated that this move will help stabilize costs for consumers, public health agencies, and community organizations, while supporting its goal to expand rapid nationwide delivery of naloxone.
Based in Allegan, Michigan, Padagis employs over 1,300 people worldwide and is committed to enhancing healthcare access through affordable, high-quality medications. Its over-the-counter naloxone nasal spray, designed to reverse opioid overdoses, is a key part of the company’s efforts to fight the ongoing opioid crisis.
Learn more at padagisnaloxone.com.
